Visit us at the annual ACR meeting!

About SCTC

The Scleroderma Clinical Trials Consortium (SCTC) is a charitable non-profit organization dedicated to finding better treatment for scleroderma. Member institutions of the SCTC conduct clinical treatment trials of new (and sometimes old) medications that appear promising for the treatment of scleroderma. The SCTC was started in 1994 with a handful of members and has now grown to an international membership of over 50 centers in the U.S., Canada, the U.K., and Europe. An annual meeting is held in conjunction with the annual American College of Rheumatology meeting in the Fall of the year.

In addition, members of the SCTC have organized to set up trials of their own, with funding from organizations like the Scleroderma Research Foundation, the Scleroderma Foundation, the U.S. FDA (Federal Drug Administration), and the National Institutes of Health (NIH) to study some medications already on the market but not approved for scleroderma.

The SCTC also supports research to establish standard outcome measures for clinical treatment trials so that results can be compared over time and over different patient groups.

A roster of member institutions, clinical investigators, and study coordinators is included on this site. Also listed are some current clinical trials that are endorsed by the SCTC. Patients who are interested in participating in these trials, or who would like additional information, are encouraged to contact the study coordinators at the numbers listed.

Physicians who would like to get additional information about these trials are also encouraged to contact the coordinators.

Investigators who would like to join the SCTC may contact one of the officers of the Executive Committee.

That should link back to the page with the executive committee name, location, email.

The track record so far for the SCTC is pretty impressive in terms of the number of trials conducted, but less impressive in terms of finding effective and safe treatments. We certainly have a long way to go.